No Data
No Data
Maxim Group Maintains Belite Bio(BLTE.US) With Buy Rating, Raises Target Price to $110
Belite Bio Price Target Raised to $110 From $60 at Maxim
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Mereo Biopharma Group Plc (MREO) and Fate Therapeutics (FATE)
Belite Bio Is Maintained at Buy by HC Wainwright & Co.
Belite Bio Analyst Ratings
H.C. Wainwright Maintains Belite Bio(BLTE.US) With Buy Rating, Raises Target Price to $100
No Data
No Data